CBIO

Crescent Biopharma, Inc. Common Stock
CBIO

Overview Fund Activity

35 hedge funds and large institutions have $7.2M invested in Crescent Biopharma, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 37 closing their positions.

Holders
35
Holders Change
-34
Holders Change %
-49.28%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
16
Closed
37
Calls
$675K
Puts
$44K
Net Calls
+$631K
Net Calls Change
-$823K

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$233K
2
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
$150K
3
ACM
3
ADAR1 Capital Management
Texas
$38K
4
UBS Group
4
UBS Group
Switzerland
$23.4K
5
Two Sigma Advisers
5
Two Sigma Advisers
New York
$30.6K

Top Sellers

1
NMC
1
NEA Management Company
Maryland
$0
2
OCA
2
Octagon Capital Advisors
New York
$0
3
Axa
3
Axa
France
$0
4
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$0
5
Marshall Wace
5
Marshall Wace
United Kingdom
$0
Name Market Value Shares Shares
Change 		Shares
Change %
IC
76
Ikarian Capital
Texas
– – – –
Barclays
77
Barclays
United Kingdom
$0 76 – –
1 2 3
4